Meghana Kulkarni serves as Vice President, Head of Biology at ENSEM Therapeutics. She comes to ENSEM with over 12 years of cancer genomics/translational research and biotech leadership experience in targeted oncology/immuno-oncology therapeutics. She recently led preclinical research as the Head of the Discovery Biology at Bakx Therapeutics where she directed the discovery and development of small molecules targeting the intrinsic mitochondrial apoptosis pathway.  Prior to Bakx Therapeutics, Meghana was Director of Biology at Silicon Therapeutics / Roivant Sciences. During her tenure, she built and managed a team of biologists to advance a portfolio of challenging targets through preclinical development. Meghana has also led several multi-disciplinary project teams to develop drug candidates including a first-in-class small molecule STING agonist currently in clinical evaluation. She spent several years in positions of increasing responsibility at the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute and in Oncology Bioscience at AstraZeneca where she led cross-functional teams focusing on kinase and epigenetic targets for cancer therapy. 

Meghana received her Doctor of Philosophy degree in Genetics from Michigan State University and did her postdoctoral training at Harvard Medical School in Boston.